Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 14615744.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thrombocytopenia with life-threatening hemorrhage in childhood immune thrombocytopenic purpura is rare, but effective therapeutic options are limited for the patient with bleeding. We report the efficacy of humanized anti-CD20 monoclonal antibody (rituximab, Rituxan) therapy for an infant with severe, refractory life-threatening immune thrombocytopenic purpura.
Medical subject headings
- Antibodies, Monoclonal
- Antigens, CD20
- Antineoplastic Agents
- Purpura, Thrombocytopenic, Idiopathic